Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097494 | 0.96 | CYP2D6 (0.46) | SIGMAR1CYP2D6CAPN1 | |
| SCHEMBL13097492 | 0.89 | POLB (0.48) | CYP2D6CAPN1 | |
| SCHEMBL13097485 | 0.85 | CYP2D6 (0.61) | CYP2D6 | |
| SCHEMBL14574432 | 0.83 | CYP2D6 (0.51) | CYP2D6CAPN1 | |
| SCHEMBL13097484 | 0.80 | POLB (0.53) | CYP2D6CAPN1 | |
| SCHEMBL13097556 | 0.77 | L3MBTL1 (0.54) | CYP2D6CAPN1 | |
| SCHEMBL5270095 | 0.76 | PTGS2 (0.65) | CAPN1 | |
| SCHEMBL8024152 | 0.76 | CYP2D6 (0.51) | CYP2D6CAPN1 | |
| SCHEMBL13097929 | 0.75 | CAPN1 (0.46) | CYP2D6CAPN1 | |
| SCHEMBL3096262 | 0.75 | CAPN1 (0.48) | CYP2D6CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | SIGMAR1 3341/4885CYP2D6 230/4885CAPN1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.